JPH0517469A - Synthetic intermediate for macrolide - Google Patents

Synthetic intermediate for macrolide

Info

Publication number
JPH0517469A
JPH0517469A JP2606991A JP2606991A JPH0517469A JP H0517469 A JPH0517469 A JP H0517469A JP 2606991 A JP2606991 A JP 2606991A JP 2606991 A JP2606991 A JP 2606991A JP H0517469 A JPH0517469 A JP H0517469A
Authority
JP
Japan
Prior art keywords
solvent
formula
group
macrolide
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2606991A
Other languages
Japanese (ja)
Inventor
Takeshi Oishi
武 大石
Tadashi Nakada
忠 中田
Toshiya Komatsu
俊哉 小松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKEN Institute of Physical and Chemical Research
Original Assignee
RIKEN Institute of Physical and Chemical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIKEN Institute of Physical and Chemical Research filed Critical RIKEN Institute of Physical and Chemical Research
Priority to JP2606991A priority Critical patent/JPH0517469A/en
Publication of JPH0517469A publication Critical patent/JPH0517469A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To obtain as a synthetic intermediate for macrolides useful as antiulcer agents, antimicrobial agents, etc. CONSTITUTION:A compound expressed by formula I (R<1> is tert. butyldiphenylsilyl, tert. butyldimethylsilyl, methoxymethyl, acetyl or benzoyl). The compound is obtained by reacting a compound expressed by formula II (Me is methyl) with tert. BuPh2SiCl and imidazole used as reagents in a solvent of DMF at 0 deg.C to ambient temperature for 1-5hr. Lactol expressed by formula II is obtained by reacting a lactone expressed by formula III with a diisobutylalminamhydride reagent in a solvent such as toluene. By using this intermediate, macrolides can be stereoselectively produced in high yield and purity.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、マクロライドの合成中
間体に関し、さらに詳細には、スウィンホライドA、ビ
ステオネルライドA及びC等の合成中間体に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to synthetic intermediates for macrolides, and more particularly to synthetic intermediates such as Swinholide A, bisteonellide A and C.

【0002】[0002]

【従来の技術】スウィンホライドA()は、沖縄産の
海綿Theonella Swinhoeiより単離され、最近北川らによ
って絶対構造が決定された結果、二量体マクロライドで
あることが判明した(I. Kitagawa, et al., J. Am. Ch
em. Soc.,112, 3710(1990))。この化合物は抗腫瘍活
性、抗菌活性なる作用を有することが知られれいる(S.
Carmely, Y. Kashman, Tetrahedron Lett.,26, 511(19
85)及び M. Kobayashi, et. al., Tetrahedron Lett.,
30, 2963(1989))。
2. Description of the Related Art Swinholide A ( 1 ) was isolated from the Okinawan sponge Theonella Swinhoei , and its absolute structure was recently determined by Kitagawa et al. . Kitagawa, et al., J. Am. Ch
em. Soc., 112, 3710 (1990)). This compound is known to have antitumor activity and antibacterial activity (S.
Carmely, Y. Kashman, Tetrahedron Lett., 26 , 511 (19
85) and M. Kobayashi, et. Al., Tetrahedron Lett.,
30, 2963 (1989)).

【0003】[0003]

【化4】 [Chemical 4]

【0004】また、スウィンホライドAの構造類縁化合
物としては、ビステオネルライドA()及びB(
が知られている。これらの化合物についても、抗腫瘍活
性なる作用を有することが知られている(R. Sakai,T.
Higa, Y. Kashman, Chem. Lett., 1499(1986)、N. Fuse
tani,T. Higa, Y.Kashman, et al., Tetrahedron Let
t., 28, 6225(1987)、及びI. Kitagawa, et al., 32nd
Symposium on the Chemistry of Natural Products, Ch
iba, Oct. 1990、Symposium Papers, P.127)。
Further, as structural analogs of Swinholide A, bistionellide A ( 2 ) and B ( 3 )
It has been known. These compounds are also known to have antitumor activity (R. Sakai, T.
Higa, Y. Kashman, Chem. Lett., 1499 (1986), N. Fuse
tani, T.Higa, Y.Kashman, et al., Tetrahedron Let
t., 28 , 6225 (1987), and I. Kitagawa, et al., 32nd.
Symposium on the Chemistry of Natural Products, Ch
iba, Oct. 1990, Symposium Papers, P. 127).

【0005】[0005]

【化5】 [Chemical 5]

【0006】しかるに、これらのマクロライドを化学的
に合成する方法は知られていなかった。
However, a method for chemically synthesizing these macrolides has not been known.

【0007】[0007]

【発明が解決しようとする課題】そこで、本発明は、上
記のマクロライドの合成中間体を提供することを目的と
する。また、本発明は、上記のマクロライドの合成中間
体を立体選択的に、かつ高収率、高純度で合成するため
の合成中間体を提供することを目的とする。
SUMMARY OF THE INVENTION It is, therefore, an object of the present invention to provide a synthetic intermediate of the above macrolide. Another object of the present invention is to provide a synthetic intermediate for stereoselectively synthesizing the above-mentioned macrolide synthetic intermediate in high yield and high purity.

【0008】[0008]

【課題を解決するための手段】本発明者らは、鋭意努力
した結果、スウィンホライドA()、ビステオネルラ
イドA()及びC()の側鎖のテトラヒドロフラン
環に相当する構造を有する化合物を合成することによ
り、本発明を完成させるに至った。すなわち、本発明
は、(1)式Iで示されるマクロライド合成中間体。
As a result of diligent efforts, the inventors of the present invention corresponded to the side-chain tetrahydrofuran ring of Swinholide A ( 1 ), Bistionellide A ( 2 ) and C ( 3 ). The present invention has been completed by synthesizing a compound having a structure. That is, the present invention provides (1) a macrolide synthetic intermediate represented by the formula I.

【0009】[0009]

【化6】 [Chemical 6]

【0010】(2)式IIで示されるマクロライド合成中
間体。
(2) A macrolide synthetic intermediate represented by the formula II.

【0011】[0011]

【化7】 [Chemical 7]

【0012】(3)式III で示されるマクロライド合成
中間体。
(3) A macrolide synthetic intermediate represented by the formula III.

【0013】[0013]

【化8】 [Chemical 8]

【0014】式IにおけるR1 の例としては、ターシャ
リーブチルジフェニルシリル基、ターシャリーブチルジ
メチルシリル基、メトキシメチル基、アセチル基、ベン
ゾイル基等を例示することができる。このうち、ターシ
ャリーブチルジフェニルシリル基が好ましい。 式IIにおけるR2 の例としては、ターシャリーブチルジ
フェニルシリル基、ターシャリーブチルジメチルシリル
基、メトキシメチル基、アセチル基、ベンゾイル基等を
例示することができる。このうち、ターシャリーブチル
ジフェニルシリル基が好ましい。
Examples of R 1 in the formula I include tert-butyldiphenylsilyl group, tert-butyldimethylsilyl group, methoxymethyl group, acetyl group and benzoyl group. Of these, the tertiary butyldiphenylsilyl group is preferable. Examples of R 2 in Formula II include a tert-butyldiphenylsilyl group, a tert-butyldimethylsilyl group, a methoxymethyl group, an acetyl group, a benzoyl group and the like. Of these, the tertiary butyldiphenylsilyl group is preferable.

【0015】式IIにおけるR3 の例としては、酸素原
子、水酸基、メトキシ基等を例示することができる。こ
のうち、酸素原子、水酸基、メトキシ基が好ましい。 式III におけるR4 の例としては、アリル基、アセトア
ルデヒド基、3−ヒドロキシプロピル基、シアノ基、酢
酸エステル基等を例示することができる。このうち、ア
リル基、アセトアルデヒド基、3−ヒドロキシプロピル
基が好ましい。
Examples of R 3 in the formula II include oxygen atom, hydroxyl group, methoxy group and the like. Of these, oxygen atom, hydroxyl group and methoxy group are preferable. Examples of R 4 in Formula III include an allyl group, an acetaldehyde group, a 3-hydroxypropyl group, a cyano group, and an acetic acid ester group. Of these, an allyl group, an acetaldehyde group, and a 3-hydroxypropyl group are preferable.

【0016】式及び式で示される化合物は、上記の
で示されるマクロライドに共通なテトラヒドロ
ピラン環セグメントを有し、上記のマクロライドの合成
における重要な中間体となる。以下、本発明のマクロラ
イドの合成中間体及びその製造方法の1例をスキームに
示すが、本発明は以下の反応スキームに限定されること
はない。
The compounds represented by the formulas 4 and 5 have a tetrahydropyran ring segment common to the macrolides represented by the formulas 1 and 2 , and are important intermediates in the synthesis of the above macrolides. Hereinafter, one example of the synthetic intermediate of the macrolide of the present invention and a method for producing the same will be shown in a scheme, but the present invention is not limited to the following reaction scheme.

【0017】スキーム中、Meはメチル基を、TBDP
Sはターシャリーブチルジフェニルシリル基を、Etは
エチル基を示す。また、スキーム中、DIBAHはジイ
ソブチルアルミナムヒドリドを、DMFはジメチルホル
ムアミドを、NBSはN−ブロムサクシンイミドを表
す。
In the scheme, Me is a methyl group and TBDP
S represents a tertiary butyldiphenylsilyl group, and Et represents an ethyl group. Further, in the scheme, DIBAH represents diisobutylaluminum hydride, DMF represents dimethylformamide, and NBS represents N-bromosuccinimide.

【0018】[0018]

【化9】 [Chemical 9]

【0019】[0019]

【化10】 [Chemical 10]

【0020】[0020]

【化11】 [Chemical 11]

【0021】[0021]

【化12】 [Chemical 12]

【0022】[0022]

【化13】 [Chemical 13]

【0023】[0023]

【化14】 [Chemical 14]

【0024】[0024]

【化15】 [Chemical 15]

【0025】上記反応スキームにおいて、好適に使用で
きる試薬、反応条件等を以下に記す。 1 溶媒 トルエン、塩化メチレン、テトラヒドロフ
ラン 温度 −78〜−30℃ 時間 0.5〜5時間 試薬 DIBAH 2 溶媒 DMF 温度 0℃〜室温 時間 1〜5時間 試薬 t-BuPh2SiCl, イミダゾール 3 溶媒 CH3CN-H2O 温度 0℃〜室温 時間 10分〜3時間 試薬 NBS 4 10 (1) 溶媒 Et2O,THF 温度 0℃〜室温 時間 0.5分〜5時間 試薬 LiAlH4, LiBH4, Zn(BH4)2 (2) 溶媒 MeOH, EtOH 温度 0℃〜室温 時間 0.5〜5時間 試薬 NaBH4 1011 溶媒 THF, DMF 温度 0℃〜室温 時間 0.5分〜5時間 試薬 MeI, KH 又は NaH 6 1112 溶媒 CH2Cl2, CH3CN 温度 −30℃〜室温 時間 10分〜5時間 試薬 アリルトリメチルシラン、BF3・Et2O, トリ
メチルシリルトリフレート 7 12 溶媒 MeOH, EtOH, EtOAc 温度 −78〜−40℃ 時間 10分〜5時間 試薬 O3, Me2S 又は Ph3P 8 12 溶媒 MeOH, EtOH, EtOAc 温度 −78℃〜室温 時間 10分〜5時間 試薬 O3, NaBH4
In the above reaction scheme, reagents and reaction conditions which can be preferably used are described below. 1 67 solvent toluene, methylene chloride, tetrahydrofuran Temperature -78 to-30 ° C. Time 0.5-5 hours reagent DIBAH 2 78 solvent DMF Temperature 0 ° C. ~ rt time 1-5 hours Reagent t-BuPh 2 SiCl, Imidazole 3 89 solvent CH 3 CN-H 2 O temperature 0 ° C ~ room temperature time 10 minutes ~ 3 hours Reagent NBS 4 910 (1) solvent Et 2 O, THF temperature 0 ° C ~ room temperature time 0.5 minutes ~ 5 hours Reagent LiAlH 4, LiBH 4 , Zn (BH 4 ) 2 (2) Solvent MeOH, EtOH Temperature 0 ° C to room temperature Time 0.5 to 5 hours Reagent NaBH 4 5 1011 solvent THF, DMF Temperature 0 ° C to room temperature time 0.5 minutes to 5 hours reagent MeI, KH or NaH 6 1112 solvent CH 2 Cl 2, CH 3 CN temperature -30 ° C. ~ room temperature for 10 minutes to 5 hours reagent allyltrimethylsilane, BF 3 · Et 2 O , trimethylsilyl triflate 7 124 solvent MeOH, EtOH, EtOAc temperature -78 to-40 ° C. for 10 minutes to 5 During reagents O 3, Me 2 S or Ph 3 P 8 125 solvent MeOH, EtOH, EtOAc temperature -78 ° C. ~ room temperature for 10 minutes to 5 hours Reagent O 3, NaBH 4

【0026】[0026]

【実施例】以下の実施例により、本発明の好ましい1実
施態様を詳細に説明する。本発明の範囲は、この実施例
に限定されるものではない。尚、本実施例中の化合物の
番号は、スキーム中の化合物の番号と一致する。 〔例1〕化合物の合成 S−(+)−ターシャリーブチル−3−ヒドロキシブタ
ノエート(>99%ee, チッソ社製)25gを用いて、
中田ら(T. Nakata, et al, Tetrahedron Lett.,26, 73
(1985)) に記載の方法により、化合物20.9gを合成
した(収率65%)。 〔例2〕 Ar 下、ラクトン(2.048g、10.0mmole)をトル
エン(60ml)に溶解し、−78℃でDIBAH(1.7
6M n−ヘキサン溶液、22.78ml、40.1mmole 、
4当量)を滴下、同温で1時間撹拌した。反応後、−7
8℃でi−プロパノール(4ml)とH2O(4ml)を滴下
し、室温で20分間撹拌したのち酢酸エチルにて希釈、
MgSO4 で乾燥し、溶媒留去して1.97gの淡黄色オイル
を得た。これをカラムクロマトグラフィー(シリカゲル
50g、ヘキサン:酢酸エチル=5:1→3:1)にて
精製し、(無色オイル、1.825g、88%)を得
た。
The following example illustrates in detail one preferred embodiment of the present invention. The scope of the invention is not limited to this example. The numbers of the compounds in this example are the same as the numbers of the compounds in the scheme. [Example 1] Synthesis of compound 6 Using 25 g of S-(+)-tert-butyl-3-hydroxybutanoate (> 99% ee, manufactured by Chisso Corporation),
Nakata et al. (T. Nakata, et al, Tetrahedron Lett., 26 , 73
(1985)), 20.9 g of Compound 6 was synthesized (yield 65%). Example 2 Lactone 6 (2.048 g, 10.0 mmole) was dissolved in toluene (60 ml) under 678 Ar and DIBAH (1.7
6M n-hexane solution, 22.78 ml, 40.1 mmole,
(4 equivalents) was added dropwise, and the mixture was stirred at the same temperature for 1 hour. After the reaction, -7
I-Propanol (4 ml) and H 2 O (4 ml) were added dropwise at 8 ° C., and the mixture was stirred at room temperature for 20 minutes and then diluted with ethyl acetate,
It was dried with MgSO 4 and the solvent was distilled off to obtain 1.97 g of a pale yellow oil. This was purified by column chromatography (silica gel 50 g, hexane: ethyl acetate = 5: 1 → 3: 1) to obtain 7 (colorless oil, 1.825 g, 88%).

【0027】ラクトール(200mg、0.97mmole)を
DMF(1ml)に溶解し、氷冷下イミダゾール(198
mg、2.9mmole 、3当量)、t BuPh2SiCl(378μl、
1.45mmole 、1.5当量)を順次加え、室温で2時間撹
拌した。反応後、酢酸エチルにて希釈し、飽和NaClで洗
浄、MgSO4 乾燥ののち溶媒留去して444mgの無色オイ
ルを得た。これをカラムクロマトグラフィー(シリカゲ
ル12g、ヘキサン:酢酸エチル=7:1)にて精製
し、(無色オイル、309mg、99%)を得た。
Lactol 7 (200 mg, 0.97 mmole) was dissolved in DMF (1 ml) and imidazole (198) was added under ice cooling.
mg, 2.9 mmole, 3 equivalents), t BuPh 2 SiCl (378 μl,
(1.45 mmole, 1.5 eq) were added successively and the mixture was stirred at room temperature for 2 hours. After the reaction, the reaction mixture was diluted with ethyl acetate, washed with saturated NaCl, dried over MgSO 4 , and evaporated to give 444 mg of colorless oil. This was purified by column chromatography (silica gel 12 g, hexane: ethyl acetate = 7: 1) to obtain 8 (colorless oil, 309 mg, 99%).

【0028】NMR(500MHz, CDCl3):δ 4.77(dd, J=2.2,
9.2Hz, 1H, Si-O-CH-O)、3.45(d,d, d, d, J=16.9, 6.
2, 6.2, 1.8Hz, 1H, CH3-C-O) 、2.21、1.89(each d
dd,J=13.2, 2.2, 2.2Hz, 1H×2, -CH-(eq))、2.04(dd,
J=13.2, 9.0Hz, 1H, -CH-(ax)) 、1.78(dd, J=13.2, 1
0.8Hz, 1H, -CH-(ax))、1.16(d, J=6.2Hz, 3H, CH3-)。 〔例3〕 Ar 下、Na2CO3(335mg、3.2mmole)のH2O(2ml)溶
液に、AgNO3(1.074g、6.3mmole)のCH3CN(6ml)溶
液を加え、室温で10分間撹拌した後、NBS(1.02
3g、5.7mmole)を氷冷下に加え、同温で5分間撹拌し
た。次いで、チオアセタール(426mg、0.96mmol
e)のCH3CN(3ml)−H2O(1ml)溶液を0℃で加え、同温
で20分間撹拌した。反応後、飽和Na2SO3(4ml)を0
℃で加えてCH2Cl2で希釈し、セライトでろ過したのちセ
ライト層をエチルエーテルでよく洗い、有機層を合して
飽和NaHCO3、飽和NaClで順次洗浄した。MgSO4 にて乾燥
し、溶媒留去して581mgの淡黄色プリズム晶とオイル
の混合物を得た。これをカラムクロマトグラフィー(シ
リカゲル8g、ヘキサン:酢酸エチル=8:1)にて精
製し、(淡黄色オイル、333mg、94%)を得た。
NMR (500 MHz, CDCl 3 ): δ 4.77 (dd, J = 2.2,
9.2Hz, 1H, Si-O-CH-O), 3.45 (d, d, d, d, J = 16.9, 6.
2, 6.2, 1.8Hz, 1H, CH 3 -C H -O), 2.21, 1.89 (each d
dd, J = 13.2, 2.2, 2.2Hz, 1H × 2, -CH- (eq)), 2.04 (dd,
J = 13.2, 9.0Hz, 1H, -CH- (ax)), 1.78 (dd, J = 13.2, 1
0.8Hz, 1H, -CH- (ax)), 1.16 (d, J = 6.2Hz, 3H, CH 3- ). Example 3 Under 89 Ar, a solution of Na 2 CO 3 (335 mg, 3.2 mmole) in H 2 O (2 ml) was added to a solution of AgNO 3 (1.074 g, 6.3 mmole) in CH 3 CN (6 ml). Was added and stirred at room temperature for 10 minutes, and then NBS (1.02
3 g, 5.7 mmole) was added under ice cooling, and the mixture was stirred at the same temperature for 5 minutes. Then, thioacetal 8 (426 mg, 0.96 mmol
A CH 3 CN (3 ml) -H 2 O (1 ml) solution of e) was added at 0 ° C, and the mixture was stirred at the same temperature for 20 minutes. After the reaction, saturated Na 2 SO 3 (4 ml) was added to 0.
The mixture was added at 0 ° C., diluted with CH 2 Cl 2 , filtered through Celite, the Celite layer was thoroughly washed with ethyl ether, and the organic layers were combined and washed successively with saturated NaHCO 3 and saturated NaCl. After drying over MgSO 4 , the solvent was distilled off to obtain 581 mg of a mixture of pale yellow prism crystals and oil. This was purified by column chromatography (silica gel 8 g, hexane: ethyl acetate = 8: 1) to obtain 9 (pale yellow oil, 333 mg, 94%).

【0029】NMR(500MHz, CDCl3):δ 4.84(dd, J=3.4,
7.9Hz, 1H, Si-O-CH-O)、3.45(ddd, J=6.1, 12.2, 15.
0Hz, 1H, CH3-C-O-)、2.61(dd,J=3.2, 14.6Hz, 1H, -
CH-(eq))、2.56(dd, J=7.9, 15.0Hz, 1H, -CH-(ax)) 、
1.26(d, J=6.1Hz, 3H, CH3-)。 〔例4〕10 Ar 下、ケトン(2.435g、6.6mmole)を無水Et2O
(80ml)に溶解し、LiAlH4(752mg、19.8mmole
、3当量)を氷冷下に加え、0℃で40分間撹拌し
た。反応後、0℃でH2O(750μl)、15%NaOH(7
50μl)、H2O(2.25ml)を順次加えて室温で10分
間撹拌した。更にMgSO4 (過剰量)を加えて室温で30
分間撹拌したのち固形物をろ去し、溶媒留去して2.51
gの橙色オイルを得た。これをカラムクロマトグラフィ
ー(シリカゲル100g、ヘキサン:酢酸エチル=1
0:1→3:1)にて精製し、10(黄色オイル、2.1
77g、89%)を得た。
NMR (500 MHz, CDCl 3 ): δ 4.84 (dd, J = 3.4,
7.9Hz, 1H, Si-O-CH-O), 3.45 (ddd, J = 6.1, 12.2, 15.
0Hz, 1H, CH 3 -C H -O-), 2.61 (dd, J = 3.2, 14.6Hz, 1H,-
CH- (eq)), 2.56 (dd, J = 7.9, 15.0Hz, 1H, -CH- (ax)),
1.26 (d, J = 6.1Hz, 3H, CH 3- ). Example 4 Ketone 9 (2.435 g, 6.6 mmole) was added anhydrous Et 2 O under 910 Ar.
Dissolve in (80 ml) and LiAlH 4 (752 mg, 19.8 mmole
(3 equivalents) was added under ice cooling, and the mixture was stirred at 0 ° C. for 40 minutes. After the reaction, at 0 ° C., H 2 O (750 μl), 15% NaOH (7
50 μl) and H 2 O (2.25 ml) were sequentially added, and the mixture was stirred at room temperature for 10 minutes. Add more MgSO 4 (excess amount) at room temperature to 30
After stirring for 1 minute, the solid matter was filtered off, the solvent was distilled off, and 2.51
g orange oil was obtained. This was subjected to column chromatography (silica gel 100 g, hexane: ethyl acetate = 1.
Purify with 0: 1 → 3: 1, 10 (yellow oil, 2.1
77 g, 89%).

【0030】NMR(500MHz, CDCl3):δ 4.57(dd, J=2.1,
9.2Hz, 1H, SiO-CH-O) 、3.63(q like, 1H, HO-CH-)、
3.22(m, 1H, CH3-C-O-)、2.41、1.81(each m, 1H ×
2, -CH-(eq))、1.47(ddd, J=9.5, 11.6, 11.6Hz, 1H, -
CH-(ax))、1.19(d, J=6.1Hz,3H, CH3-)。 〔例5〕1011 Ar 下、アルコール10(2.177g、5.9mmole)を無
水THF(70ml)に溶解し、CH3l(3.85ml、58.8
mmole 、10当量)およびKH(35重量%、過剰量)
を0℃で順次加え、0℃で45分間撹拌した。反応後、
0℃でH2O を加え、酢酸エチルにて抽出、飽和NH4Cl 、
飽和NaClで順次洗浄したのちMgSO4 にて乾燥し、溶媒留
去して3.43gの橙色オイルを得た。これをカラムクロ
マトグラフィー(シリカゲル100g、ヘキサン:酢酸
エチル=40:1→10:1)にて精製し、11(黄色
オイル、2.096g、93%)を得た。
NMR (500 MHz, CDCl 3 ): δ 4.57 (dd, J = 2.1,
9.2Hz, 1H, SiO-CH-O), 3.63 (q like, 1H, HO-CH-),
3.22 (m, 1H, CH 3 -C H -O-), 2.41, 1.81 (each m, 1H ×
2, -CH- (eq)), 1.47 (ddd, J = 9.5, 11.6, 11.6Hz, 1H,-
CH- (ax)), 1.19 (d, J = 6.1Hz, 3H, CH 3- ). Example 5 Alcohol 10 (2.177 g, 5.9 mmole) was dissolved in anhydrous THF (70 ml) under 1011 Ar to prepare CH 3 l (3.85 ml, 58.8 ml).
mmole, 10 eq) and KH (35 wt%, excess)
Were sequentially added at 0 ° C., and the mixture was stirred at 0 ° C. for 45 minutes. After the reaction
H 2 O was added at 0 ° C., extracted with ethyl acetate, saturated NH 4 Cl,
It was washed successively with saturated NaCl, dried over MgSO 4 , and evaporated to give 3.43 g of orange oil. This was purified by column chromatography (silica gel 100 g, hexane: ethyl acetate = 40: 1 → 10: 1) to obtain 11 (yellow oil, 2.096 g, 93%).

【0031】NMR(500MHz, CDCl3):δ 4.56(dd, J=2.1,
9.5Hz, 1H, SiO-CH-O) 、3.28(S,3H, OCH3) 、3.19(m,
2H, CH3-C-O-, CH3-C-)、2.17、1.86(each m, 1H
×2, -CH-(eq))、1.43(ddd, J=9.5, 11.6, 11.6Hz,1H,
-CH-(ax))、1.19(d, J=6.4Hz, 3H, CH3-)。 〔例6〕1112 Ar 下、シリル体11(75mg、0.20mmole)をCH2Cl2
(1ml)に溶解し、0℃でアリルトリメチルシラン(9
3μl,0.6mmole 、3当量)およびBF3・Et 2O(74
μl、0.6mmole 、3当量)を順次加え、0℃で35分
間撹拌した。反応後、0℃で飽和NaHCO3を加え、Et2Oで
希釈したのち飽和NaHCO3、飽和NaClで順次洗浄し、MgSO
4 乾燥、溶媒留去して82mgの無色オイルを得た。これ
をカラムクロマトグラフィー(シリカゲル5g、ヘキサ
ン:酢酸エチル=15:1→5:1)にて精製し、12
(無色オイル、80mg、>100%)を得た。これをCH
3OH(5ml)に溶解し、−78℃でオゾン発生器より調製
したO3 ガスを通じつつ20分間撹拌した。Ar ガスを
通じた後、−78℃で(CH3)2S(2.5ml)を加え、室温で
11時間撹拌した。反応後、CH3OH と(CH3)2S を留去し
て、82mgの無色オイルを得た。これをカラムクロマト
グラフィー(シリカゲル5g、ヘキサン:酢酸エチル=
6:1→4:1)で精製し、(無色オイル、16mg、
11より収率46%)を得た。
NMR (500MHz, CDCl3): Δ 4.56 (dd, J = 2.1,
 9.5Hz, 1H, SiO-CH-O), 3.28 (S, 3H, OCH3), 3.19 (m,
 2H, CH3-CH-O-, CH3-CH-), 2.17, 1.86 (each m, 1H
 × 2, -CH- (eq)), 1.43 (ddd, J = 9.5, 11.6, 11.6Hz, 1H,
 -CH- (ax)), 1.19 (d, J = 6.4Hz, 3H, CH3-). [Example 6]1112Four Under Ar, silyl body11CH (75mg, 0.20mmole)2Cl2
Dissolve in (1 ml) and add allyltrimethylsilane (9
3μl, 0.6mmole, 3eq) and BF3・ Et 2O (74
μl, 0.6mmole, 3eq) were added sequentially, and at 0 ° C for 35 minutes.
It was stirred for a while. After reaction, saturated NaHCO 3 at 0 ° C3And Et2At O
After dilution, saturated NaHCO3, Washed sequentially with saturated NaCl, MgSO
FourAfter drying and evaporation of the solvent, 82 mg of colorless oil was obtained. this
Column chromatography (silica gel 5 g, hexa
: Ethyl acetate = 15: 1 → 5: 1),12
(Colorless oil, 80 mg,> 100%) was obtained. CH this
3Dissolve in OH (5 ml) and prepare from ozone generator at -78 ℃
Done O3Stir for 20 minutes while passing gas through. Ar gas
Then, at -78 ° C (CH3)2Add S (2.5 ml) and at room temperature
Stir for 11 hours. After reaction, CH3OH and (CH3)2Evaporate S
82 mg of colorless oil was obtained. Column chromatography
Graphography (5 g silica gel, hexane: ethyl acetate =
6: 1 → 4: 1),Four(Colorless oil, 16 mg,
11Yield (46%) was obtained.

【0032】NMR(500MHz, CDCl3):δ 9.76(dd like, 1
H, CHO) 、4.69(ddd like,1H,OHC-C-C-O) 、3.78(m,
1H, CH3-C-O-)、3.51(ddd like, 1H, CH3O-C-)、
3.34(s, 3H, OCH3) 、2.81、2.48(each ddd, 1H ×2,
-OCH-C 2-) 、1.98、1.81(each m, 1H ×2, -CH-(e
q))、1.72(ddd, 1H, -CH-(ax)) 、1.23(d, J=6.4Hz, 3
H, CH3-)。 〔例7〕1112 Ar 下、シリル体11(2.169g、5.6mmole)をCH2C
l2(30ml)に溶解し、0℃でアリルトリメチルシラン
(2.7ml、17.0mmole 、3当量)およびBF3 ・ジエチ
ルエーテル(2.13ml、17.0mmole 、3当量)を順次
加え、途中アリルトリメチルシラン(0.45ml、0.5当
量)およびBF3 ・ジエチルエーテル(0.355ml、0.5
当量)を追加しつつ、0℃で1時間40分間撹拌した。
反応後、0℃で飽和NaHCO3を加え、ジエチルエーテルに
て希釈したのち飽和NaHCO3、飽和NaClで順次洗浄し、Mg
SO4 乾燥、溶媒留去して2.54gの黄色オイルを得た。
これをカラムクロマトグラフィー(シリカゲル100
g、ヘキサン:酢酸エチル=10:1→5:1)にて精
製し、12(淡黄色オイル、1.570mg、>100%)
を得た。このものをCH3OH(20ml)に溶解し、−78℃
でオゾン発生器より調製したO3 ガスを通じつつ30分
間撹拌した。更に0℃に冷却したNaBH4(1.687g、4
5.1mmole)のMeOH(10ml)溶液を−78℃から0℃ま
で昇温しながら加え、0℃で15分間、室温で15分間
撹拌した。反応後、飽和NH4Cl を加え、酢酸エチルで1
0回抽出したのちH2O 、飽和NaClで順次洗浄し、MgSO4
乾燥、溶媒留去して1.44gの淡黄色オイルを得た。こ
れをカラムクロマトグラフィー(シリカゲル50g、ヘ
キサン:酢酸エチル=2:1→酢酸エチル)にて精製
し、(無色オイル、677mg、11より収率69%)
を得た。
NMR (500 MHz, CDCl 3 ): δ 9.76 (dd like, 1
H, CHO), 4.69 (ddd like, 1H, OHC-CC H -O), 3.78 (m,
1H, CH 3 -C H -O-), 3.51 (ddd like, 1H, CH 3 OC H- ),
3.34 (s, 3H, OCH 3 ), 2.81, 2.48 (each ddd, 1H × 2,
-OCH-C H 2- ), 1.98, 1.81 (each m, 1H × 2, -CH- (e
q)), 1.72 (ddd, 1H, -CH- (ax)), 1.23 (d, J = 6.4Hz, 3
H, CH 3- ). [Example 7] Under 11125 Ar, the silyl compound 11 (2.169 g, 5.6 mmole) was converted into CH 2 C.
Dissolve in l 2 (30 ml), add allyltrimethylsilane (2.7 ml, 17.0 mmole, 3 equivalents) and BF 3 · diethyl ether (2.13 ml, 17.0 mmole, 3 equivalents) at 0 ° C., and in the middle Allyltrimethylsilane (0.45 ml, 0.5 eq) and BF 3 .diethyl ether (0.355 ml, 0.5)
(Equivalent weight) was added and the mixture was stirred at 0 ° C. for 1 hour and 40 minutes.
After the reaction, saturated NaHCO 3 was added at 0 ° C., diluted with diethyl ether, and washed successively with saturated NaHCO 3 and saturated NaCl.
SO 4 was dried and the solvent was distilled off to obtain 2.54 g of a yellow oil.
Column chromatography (silica gel 100
g, hexane: ethyl acetate = 10: 1 → 5: 1), 12 (pale yellow oil, 1.570 mg,> 100%)
Got Dissolve this in CH 3 OH (20 ml) and -78 ℃
Then, the mixture was stirred for 30 minutes while passing O 3 gas prepared from the ozone generator. Further cooled to 0 ° C NaBH 4 (1.687 g, 4
A solution of 5.1 mmole) in MeOH (10 ml) was added while raising the temperature from -78 ° C to 0 ° C, and the mixture was stirred at 0 ° C for 15 minutes and at room temperature for 15 minutes. After the reaction, add saturated NH 4 Cl and add 1 with ethyl acetate.
After being extracted 0 times, it is washed successively with H 2 O and saturated NaCl, then MgSO 4
After drying and evaporation of the solvent, 1.44 g of a pale yellow oil was obtained. This was purified by column chromatography (silica gel 50 g, hexane: ethyl acetate = 2: 1 → ethyl acetate), 5 (colorless oil, 677 mg, yield 69% from 11 )
Got

【0033】NMR(500MHz, CDCl3):δ 4.27(ddd like,
1H, HO-C-C-C-O-)、3.86(m, 1H,CH3-C-O-)、3.77
(m, 2H, HO-CH2 -)、3.54(ddd like,1H, CH3-CH-) 、3.3
4(s, 3H, OCH3) 、2.07(m, 1H, HO-C-C-)、1.97、1.8
0(each m, 1H ×2, -CH-(eq))、1.65、1.52(ddd, 1H×2
、-CH-(ax)) 、1.24(d, J=6.4Hz, 3H, CH3-)。〔α〕
D 22.5 −42.6゜(,2.47 ; CHCl3)
NMR (500 MHz, CDCl 3 ): δ 4.27 (ddd like,
1H, HO-CCC H -O-), 3.86 (m, 1H, CH 3 -C H -O-), 3.77
(m, 2H, HO-C H 2- ), 3.54 (ddd like, 1H, CH 3 -CH-), 3.3
4 (s, 3H, OCH 3 ), 2.07 (m, 1H, HO-CC H- ), 1.97, 1.8
0 (each m, 1H × 2, -CH- (eq)), 1.65, 1.52 (ddd, 1H × 2
, -CH- (ax)), 1.24 (d, J = 6.4Hz, 3H, CH 3- ). [Α]
D 22.5 -42.6 ° (c, 2.47; CHCl 3)

【0034】[0034]

【発明の効果】本発明により合成されるマクロライド合
成中間体は、スウィンホライドA、ビステオネルライド
A及びC等のマクロライドの合成に用いることができ
る。本発明の合成中間体により製造できるマクロライド
は、顕著な抗腫瘍活性、抗菌活性を有する化合物であ
り、抗腫瘍剤、抗菌剤として利用することができる。
INDUSTRIAL APPLICABILITY The macrolide synthesis intermediate synthesized according to the present invention can be used for the synthesis of macrolides such as swinholide A, bisteonellide A and C. The macrolide that can be produced by the synthetic intermediate of the present invention is a compound having remarkable antitumor activity and antibacterial activity, and can be used as an antitumor agent or an antibacterial agent.

【0035】また本発明のマクロライドの合成中間体に
より、立体選択的に、かつ高収率、高純度で目的とする
マクロライドを製造することができる。
The macrolide synthetic intermediate of the present invention can stereoselectively produce a desired macrolide in high yield and high purity.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 式Iで示されるマクロライド合成中間
体。 【化1】
1. A macrolide synthesis intermediate of formula I. [Chemical 1]
【請求項2】 式IIで示されるマクロライド合成中間
体。 【化2】
2. A macrolide synthetic intermediate of formula II. [Chemical 2]
【請求項3】 式III で示されるマクロライド合成中間
体。 【化3】
3. A macrolide synthetic intermediate of formula III. [Chemical 3]
JP2606991A 1991-02-20 1991-02-20 Synthetic intermediate for macrolide Pending JPH0517469A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2606991A JPH0517469A (en) 1991-02-20 1991-02-20 Synthetic intermediate for macrolide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2606991A JPH0517469A (en) 1991-02-20 1991-02-20 Synthetic intermediate for macrolide

Publications (1)

Publication Number Publication Date
JPH0517469A true JPH0517469A (en) 1993-01-26

Family

ID=12183393

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2606991A Pending JPH0517469A (en) 1991-02-20 1991-02-20 Synthetic intermediate for macrolide

Country Status (1)

Country Link
JP (1) JPH0517469A (en)

Similar Documents

Publication Publication Date Title
CN102630226A (en) Entecavir synthesis method and intermediate compound thereof
EP0224938B1 (en) Intermediates for the production of podophyllotoxin and related compounds and processes for the preparation and use thereof
JP2003521546A (en) Synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one
HU196732B (en) Process for producing intermediates of prostaglandin derivatives
US4940797A (en) Process for synthesis of FK-506 C10-C18 intermediates
JPH0517469A (en) Synthetic intermediate for macrolide
JPH03176464A (en) Production of optically active cyclopentanone derivative
JP2005512977A (en) Process for the preparation of 14 beta-hydroxy-baccatin III-1,14-carbonate
US5155228A (en) FK-506 C10-C18 process intermediates
JPH05229975A (en) Cyclopentenol derivative
JP3655939B2 (en) Novel process for the preparation of 13-alkyl milbemycin intermediates
JP3403761B2 (en) 3,5-Dihydroxy-1-octen-7-ynes and method for producing the same
JP2869745B2 (en) Optically active dichlorlactone compound, method for producing the same, and method for producing optically active diol compound using the same
JP2831549B2 (en) Method for producing 24-oxocholesterols
JP2718546B2 (en) Stereoselective production of cyclopentenone derivatives
JP3249847B2 (en) Method for producing Z-cyclohexylideneacetic acid derivative
JPH07330656A (en) Intermediate for synthesis of taxol and production thereof
JP2001131196A (en) Method for producing cordycepin derivative
JPH03220158A (en) Preparation of optically active carbacycline derivative
JP2001240575A (en) Preparation method of optically active enone and intermediate
JPS61275272A (en) Production of gamma-butyrolactone derivative
JPH05239062A (en) Synthesis of intermediate for synthesizing mycalamide
JPS61100538A (en) Novel cyclopentene alcohol compound and its preparation
JPS6299343A (en) Homophthalic acid derivative and acid anhydride thereof
JPH05339254A (en) Production of hydroxylactone compound